Xilio Therapeutics, Inc.
XLO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $104 | $122 | $89 | $55 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $20 | $2 | $4 | $5 |
| Total Curr. Assets | $124 | $124 | $93 | $60 |
| Property Plant & Equip (Net) | $8 | $8 | $9 | $9 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $2 | $2 | $2 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $2 | $0 | $0 | $0 |
| Total NC Assets | $10 | $10 | $11 | $11 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $134 | $134 | $104 | $71 |
| Liabilities | – | – | – | – |
| Payables | $2 | $4 | $2 | $3 |
| Short-Term Debt | $1 | $1 | $1 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $44 | $42 | $40 | $14 |
| Other Curr. Liab. | $9 | $6 | $4 | $10 |
| Total Curr. Liab. | $56 | $53 | $48 | $27 |
| LT Debt | $6 | $6 | $7 | $7 |
| Deferred Rev, NC | $0 | $29 | $39 | $19 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $79 | $39 | $0 | $0 |
| Total NC Liab. | $85 | $73 | $45 | $26 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $8 | $8 | $8 |
| Total Liabilities | $142 | $127 | $93 | $53 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $54 | $0 | $0 | $0 |
| Retained Earnings | -$429 | -$413 | -$397 | -$384 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $367 | $420 | $408 | $401 |
| Total Equity | -$8 | $7 | $11 | $18 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $134 | $134 | $104 | $71 |
| Net Debt | -$97 | -$114 | -$81 | -$47 |